Strong Preference for ctDNA Propelling the Growth of Liquid Biopsy Market

2026-07-06 10:32:44 Health and Fitness

579

According to a new research report by RNCOS entitled, Global Liquid Biopsy Market Outlook to 2020, innovation and technological advancements based on circulating tumor DNA approach are driving the liquid biopsy market

Circulating tumor DNA levels differentiate early advanced tumors in a wide variety of cancers. Researchers found that circulating tumor DNA was detectable in over 75% of advanced pancreatic, ovarian, colorectal, bladder, gastro-esophageal, breast, melanoma, hepato-cellular, and head and neck cancers.

Future researches have shown strong preference for circulating tumor DNA, among the various biomarkers used for liquid biopsy. Most of the current research and commercialization are also inclined towards circulating tumor DNA.

Monitoring circulating tumor DNA is expected to provide clinicians with faster, cheaper, less invasive ways to assess cancer patients' clinical status and response to therapy. Circulating tumor DNA assay for multiple genes via next-generation sequencing might turn out to be a liquid biopsy alternative to invasive tissue biopsy. The ability to isolate this circulating tumor DNA gives physicians greater insights about cancer mutations and how they react to treatment.

Circulating tumor DNA detection has great potential in cancer diagnose, monitoring, predicting survival. Multigene panel analysis of Circulating tumor DNA may lead to increased test sensitivity. Consequently, the development of appropriate biomarkers and more accurate detection methods based on circulating tumor DNA could benefit a lot to cancer patients and may as a result improve the clinical outcome in the near future.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM815.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.